All News
Evaluation of Bimekizumab in PsA
Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.
Read Article
The METEOR study reveals distinct clinical features in spondyloarthritis (SpA) patients with vs. without IBD.
Key features of those with IBD:
- Lower male prevalence
- Higher uveitis rates
- Lower psoriasis rates
- More structural damage in SI joints
Mirroring gut… https://t.co/EyBZQ91DDn
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Another abstract #0650 highlighting the impact of tubulointerstitial inflammation predicting risk of CKD/ESRD in lupus nephritis
@RheumNow #ACR24 https://t.co/XYwO0xnWNR
Akhil Sood MD AkhilSoodMD ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
IV or inhaled THC:
Works quickly with high peak, feel euphoric but not sustained response
Oral is much better for medicinal usage
@RheumNow #ACR24 https://t.co/3PatgEFjZh https://t.co/wrrLMpfL5D
Links:
Eric Dein ericdeinmd ( View Tweet)
Cool data from the JAK-POT study
Have heard JAKs faster than TNF; perhaps not the case!
If anything, TNFs outperformed the others in this study
Trying not to over-read this, but supports my re-emerging preference for TNF
#ACR24 @rheumnow Abstr#0501 https://t.co/NDyPwju3ds
Links:
Mike Putman EBRheum ( View Tweet)
How to take cannabis?
Do NOT rec inhaled
- makes drug level go up high/fast, benefit for rec use but not for medicinal
- bronchitis, ?oral cancer
Other risks: psychosis - risk in youth, memory loss (poor studies), dependence, respiratory if inhaled
Clauw 16S18 #ACR24
@RheumNow https://t.co/coYNl7VOT3
Eric Dein ericdeinmd ( View Tweet)
#0513
🔬 Rituximab in RA: IgG levels & infection
➡️ 164 patients (mean age 59, IgG 14g/L, dx duration 13yrs)
🧬 IgG levels ⬇️over time (6 years/25 infusions)
⚠️ Infection-related hospitalizations peaked year 1 ⬆️risk w/ concurrent steroid(HR 2.1,p=0.002)
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
Older adults with RA receive less DMARDs, the standard of care. Dr. Bruno Fautrel shows TOC tolerance in older adults is comparable to younger patients. Let's treat the patient, not their age! #ACR24 @RheumNow ABST#0516 https://t.co/054RWGh3a7
Jiha Lee JihaRheum ( View Tweet)
Discrimination in #SLE is a chronic stressor - Asians had substantial levels along with association of worse mental health and SLE activity
Data from the California Lupus Epidemiology Study (CLUES) using the Everyday Discrimination Scale (EDS) @JYazdany @RheumNow #ACR24 abst#0171
Bella Mehta bella_mehta ( View Tweet)
Clauw: think of THC and CBD as “completely different”
Cannabidiol - safe, not psychoactive, “can use liberally”
THC - psychoactive with effects on CB1 and CB2 receptors. CB1 affects the brain where CB2 is more in inflammation
#ACR24
@RheumNow https://t.co/A0TgSpAO64
Links:
Eric Dein ericdeinmd ( View Tweet)
Cardiology 🤝 Rheumatology
#Abstract0611 highlights Subclinical atherosclerosis (carotid plaque > 1.5 mm) associated with ↑ risk of CV events in SLE longitudinal cohort
@RheumNow #ACR24 https://t.co/jLLYNOfFZ2
Akhil Sood MD AkhilSoodMD ( View Tweet)
Moderating a great talk about POTS - great slide & nice presentation technique
Dr. Adler flashed a screen of the ROS for pts w/POTs, overwhelming as expected… then overlaid common causes and phenotypes - really like this as a framework!
#ACR24 @RheumNow https://t.co/mCmtygxxv4
Mike Putman EBRheum ( View Tweet)
🚨Therapeutic target in PsO?
Abst#0067 from Cleveland Clinic evaluated pts w/ PsO at high risk for PsA (HR-PsO).
- HR-PsO: ⬆️percentage in migratory dendritic cells with elevated expression of CXCR4.
- Migratory effect ⬇️ after selective CXCR4 inhibitor. #ACR24 @ElaineHusniMD… https://t.co/nVoAThUxi1 https://t.co/8d1K3nkttI
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Implementing an automated inflammatory back pain screening tool in community rheumatology practices significantly enhances the identification of axial spondyloarthritis. With 14.3% of positive screenings leading to diagnosis.
Another innovation that may help with the rapid… https://t.co/qSwryK22uj
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#0456📱 Digital Health & RA ePROs
💻Rx response in 150 RA patients using ePROs & actigraphy
🔍Actigraphy slightly improved accuracy (86% precision, 83% v. 75% recall with ePROs alone)
💡Passive actigraphy can help classify response &⬇️ ePROs, patient burden.
#ACR24 @RheumNow
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure:
-Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie
#ACR24 @RheumNow https://t.co/Jc0cdmrVhI
Adela Castro AdelaCastro222 ( View Tweet)
Can PROs help identify high-risk #SLE patients? #Abstract0655 from the FORWARD registry shows higher SLAQ scores (including flares) and RDCI are linked to increased hospitalization risk.
@RheumNow #ACR24
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abstract 0587: Among PsA patients (bDMARD-naive & TNF non-responders) treated with Bimekizumab, better disease control was linked to improved work productivity, including ↓ work impairment, ↓ presenteeism, and ↓ activity impairment. #ACR24 @RheumNow https://t.co/sZBjJ9lk39
Akhil Sood MD AkhilSoodMD ( View Tweet)
TAPIR study of continuing vs stopping steroids in ANCA vasculitis in remission. Relapse at month 6 in 16% vs 4%. OR 4.22, but low rate in either group. If treated Rituximab, no difference! Merkel et al. @RheumNow #ACR24 Abstr#0774 #ACRbest https://t.co/pKa4U5L2fW https://t.co/MjzE14SeGi
Links:
Richard Conway RichardPAConway ( View Tweet)